Citigroup
KYNB

Citigroup’s Kyntra Bio KYNB Stock Holding History

Citigroup’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,904
Closed -$42.2K – 5708
2023
Q4 		$42.2K Sell
1,904
-356
-16% -$5.37K ﹤0.01% 4610
2023
Q3 		$48.8K Sell
2,260
-1,996
-47% -$78.4K ﹤0.01% 4150
2023
Q2 		$287K Buy
4,256
+4,236
+21,180% +$1.75M ﹤0.01% 3702
2023
Q1 		$9.33K Sell
20
-2,380
-99% -$1.26M ﹤0.01% 4760
2022
Q4 		$961K Sell
2,400
-2,300
-49% -$881K ﹤0.01% 2631
2022
Q3 		$1.53M Buy
4,700
+1,200
+34% +$386K ﹤0.01% 2359
2022
Q2 		$924K Buy
+3,500
New +$894K ﹤0.01% 2726

Other funds holding KYNB

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Citigroup's KYNB Position: Q1 2026 in Review

Citigroup opened a new position in Kyntra Bio (KYNB) in Q1 2026: 1 share worth $7. The stake represents ﹤0.01% of the portfolio and ranks #5756 among its holdings. This is a return to the name: Citigroup previously reported a position in KYNB as recently as Q3 2025.

Citigroup first reported a position in KYNB in Q4 2014 and has held it in 43 quarters since. The position peaked at $11.1M in Q1 2023. 32 funds tracked by Wall St. Rank hold KYNB as of Q1 2026.

  • Citigroup held 1 share of Kyntra Bio worth $7 as of Q1 2026.
  • Kyntra Bio was a new Citigroup position in Q1 2026.
  • Kyntra Bio made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5756 holding.
  • Citigroup first reported a position in Kyntra Bio in Q4 2014 and has held it in 43 quarters since.
  • Citigroup's Kyntra Bio position peaked at $11.1M in Q1 2023.
  • 32 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.